Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Activist investor Starboard Value has fully exited its position in Pfizer, marking the end of a high-profile effort to pressure the pharmaceutical giant into boosting its flagging share price. According to a recent 13-F regulatory filing, Starboard sold approximately 8.5 million Pfizer shares during the third quarter, unwinding a stake that once totaled 15.4 million shares at the end of Q4 2024.
Starboard initially made waves when it disclosed a roughly $1 billion investment in Pfizer a year ago, stepping in at a time when the company’s stock was trading at roughly half its peak during the pandemic. The fund’s founder, Jeffrey Smith, was outspoken about Pfizer’s performance, arguing at an industry event that the board needed to hold management accountable for persistent underperformance and weak market confidence.
Despite its push for governance and operational improvements, Starboard’s campaign struggled to gain lasting traction. The firm had approached former Pfizer executives—including former CEO Ian Read—for strategic guidance, but discussions reportedly stalled. Pfizer’s current market value sits around $142 billion, a decline from roughly $162 billion when Starboard’s involvement was first revealed in October 2024.
Starboard, known for its aggressive activist strategies, has been active across several industries this year, taking positions in companies such as TripAdvisor, Rogers, and BILL Holdings, where it secured a board seat shortly after investing. However, its Pfizer exit marks a notable retreat from what was once one of its most closely watched campaigns.
The same filing also revealed that Starboard fully divested from Fortrea Holdings, a contract research organization spun off from LabCorp in 2023. The hedge fund sold 2.5 million Fortrea shares during the third quarter. Since Starboard disclosed its investment in October 2023, Fortrea’s share price has fallen nearly 50%, adding another setback to the fund’s recent positions.
Starboard declined to comment on the latest disclosures.
